Clinical trial
A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)
NCT05775094 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- March 7, 2023
- Completion date
- March 31, 2027
- Enrollment
- 10 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.